Warren Nighan JR - Jul 17, 2024 Form 4 Insider Report for ANGIODYNAMICS INC (ANGO)

Role
SVP Quality and Regulatory
Signature
/s/ Stephen A. Trowbridge, Attorney in Fact
Stock symbol
ANGO
Transactions as of
Jul 17, 2024
Transactions value $
-$12,328
Form type
4
Date filed
8/2/2024, 09:50 PM
Previous filing
Jul 22, 2022
Next filing
Jul 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANGO Common Stock Options Exercise $0 +5.68K +13.85% $0.00 46.7K Jul 17, 2024 Direct F1
transaction ANGO Common Stock Tax liability -$12.3K -1.67K -3.57% $7.40 45K Jul 17, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANGO Performance Right Options Exercise $0 +7.55K $0.00* 0 Jul 17, 2024 Common Stock 7.55K Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This acquisition of 5,677 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 21, 2021.
F2 The exempt disposition of 1,666 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 21, 2021.
F3 On July 21, 2021, the reporting person received a target grant of 7,550 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,677 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.